Novartis and CENAME seal deal to secure distribution of chronic diseases’ medication

By DOH JAMES SONKEY The drug portfolio of the National Centre for the Procurement and Supply of Essential Medicines better known by its French acronym as CENAME will henceforth be enriched by 15 medicines used in the treatment of certain cardiovascular diseases, high blood pressure, type 2 diabetes, certain respiratory diseases and breast cancer following a deal reached at last February 20, 2018 between Novartis and CENAME in Yaounde. According to the terms of the agreement signed by Novartis Social Business and Legal Head, Rodrigo Osorio Aguilar and by CENAME’s Director General, Dr Joseph Vaillam, the 15 drugs that cover…